Company Quick10K Filing
Bristol Myers Squibb
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 1,637 $73,829
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-07-25 Quarter: 2019-06-30
10-Q 2019-04-25 Quarter: 2019-03-31
10-K 2019-02-25 Annual: 2018-12-31
10-Q 2018-10-25 Quarter: 2018-09-30
10-Q 2018-07-26 Quarter: 2018-06-30
10-Q 2018-04-26 Quarter: 2018-03-31
10-K 2018-02-13 Annual: 2017-12-31
10-Q 2017-10-26 Quarter: 2017-09-30
10-Q 2017-07-27 Quarter: 2017-06-30
10-Q 2017-04-27 Quarter: 2017-03-31
10-K 2017-02-21 Annual: 2016-12-31
10-Q 2016-10-27 Quarter: 2016-09-30
10-Q 2016-07-28 Quarter: 2016-06-30
10-Q 2016-04-28 Quarter: 2016-03-31
10-K 2016-02-12 Annual: 2015-12-31
10-Q 2015-10-27 Quarter: 2015-09-30
10-Q 2015-07-23 Quarter: 2015-06-30
10-Q 2015-04-28 Quarter: 2015-03-31
10-K 2015-02-13 Annual: 2014-12-31
10-Q 2014-10-24 Quarter: 2014-09-30
10-Q 2014-07-24 Quarter: 2014-06-30
10-Q 2014-04-29 Quarter: 2014-03-31
10-K 2014-02-14 Annual: 2013-12-31
10-Q 2013-10-23 Quarter: 2013-09-30
10-Q 2013-07-25 Quarter: 2013-06-30
10-Q 2013-04-25 Quarter: 2013-03-31
10-K 2013-02-15 Annual: 2012-12-31
10-Q 2012-10-24 Quarter: 2012-09-30
10-Q 2012-07-25 Quarter: 2012-06-30
10-Q 2012-04-26 Quarter: 2012-03-31
10-K 2012-02-17 Annual: 2011-12-31
10-Q 2011-10-27 Quarter: 2011-09-30
10-Q 2011-07-28 Quarter: 2011-06-30
10-Q 2011-04-28 Quarter: 2011-03-31
10-K 2011-02-18 Annual: 2010-12-31
10-Q 2010-10-26 Quarter: 2010-09-30
10-Q 2010-07-22 Quarter: 2010-06-30
10-Q 2010-04-29 Quarter: 2010-03-31
10-K 2010-02-19 Annual: 2009-12-31
8-K 2020-02-06 Earnings, Exhibits
8-K 2019-11-21 Enter Agreement, Leave Agreement, M&A, Off-BS Arrangement, Other Events, Exhibits
8-K 2019-11-20 Enter Agreement, M&A, Off-BS Arrangement, Officers, Other Events, Exhibits
8-K 2019-11-15 Other Events, Exhibits
8-K 2019-11-15 Other Events, Exhibits
8-K 2019-11-12 Other Events, Exhibits
8-K 2019-11-07 Other Events, Exhibits
8-K 2019-11-05 Other Events, Exhibits
8-K 2019-11-01 Other Events, Exhibits
8-K 2019-10-31 Earnings, Exhibits
8-K 2019-10-30 Other Events, Exhibits
8-K 2019-10-08 Other Events, Exhibits
8-K 2019-09-23 Other Events, Exhibits
8-K 2019-07-25 Earnings, Exhibits
8-K 2019-07-01 Other Events, Exhibits
8-K 2019-06-28 Other Events, Exhibits
8-K 2019-06-24 Other Events, Exhibits
8-K 2019-06-05 Officers, Exhibits
8-K 2019-05-29
8-K 2019-05-24 Other Events, Exhibits
8-K 2019-05-16 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2019-05-07 Other Events, Exhibits
8-K 2019-05-01 Other Events, Exhibits
8-K 2019-05-01 Regulation FD, Other Events, Exhibits
8-K 2019-05-01 Other Events, Exhibits
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-04-17 Other Events, Exhibits
8-K 2019-04-12 Shareholder Vote, Other Events, Exhibits
8-K 2019-04-04 Other Events
8-K 2019-03-25 Other Events
8-K 2019-03-08 Other Events, Exhibits
8-K 2019-03-08 Officers, Exhibits
8-K 2019-01-25 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2019-01-24 Earnings, Regulation FD, Exhibits
8-K 2019-01-18 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-01-03 Regulation FD, Other Events, Exhibits
8-K 2019-01-02 Enter Agreement, Exhibits
8-K 2018-12-19 Other Events, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-09-14 Officers
8-K 2018-08-27 Officers, Exhibits
8-K 2018-07-26 Earnings, Exhibits
8-K 2018-07-17 Officers, Exhibits
8-K 2018-05-01
8-K 2018-04-26 Earnings, Exhibits
8-K 2018-03-01 Officers, Exhibits
8-K 2018-02-14 Other Events, Exhibits
8-K 2018-02-05 Earnings, Exhibits
8-K 2018-01-22 Officers
8-K 2018-01-05 Other Events

Bristol Myers Squibb Financials

BMY Metrics, Comps, Filings

Annual | Quarterly

Business

We operate in one segment-BioPharmaceuticals. For additional information about business segments, refer to "Item 8. Financial Statements and Supplementary Data-Note 1. Accounting Policies and Recently Issued Accounting Standards." Our principal strategy is to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry. Our focus as a specialty biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases. Our four strategic priorities are to drive business performance, continue to further build a leading franchise in IO, maintain a diversified portfolio both within and outside of IO, and continue our disciplined approach to capital allocation, including establishing partnerships, collaborations and in-licensing or acquiring investigational compounds as an essential component of successfully delivering transformational medicines to patients. We expect that our planned acquisition of Celgene that we announced in January 2019 will enable us to create a leading focused specialty biopharmaceutical company that is well positioned to address the needs of patients with cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. We plan to remain focused while broadening our portfolio of marketed medicines and pipeline assets. With complementary disease areas, the combined company will operate with global reach and scale, the speed and agility that is core to each company's strategic approach. For a further discussion of our strategy initiatives, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations-Strategy."

We compete with other worldwide research-based drug companies, smaller research companies and generic drug manufacturers. Our products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. We manufacture products in the U.S., Puerto Rico and in four foreign countries. Most of our revenues come from products in the following therapeutic classes: oncology; cardiovascular and immunoscience.

The percentage of revenues by significant region/country were as follows:


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646
Bausch (BHC) 8,750 0% 25.1 -3% 32,354 29,666 8,425 0 -911 1,285 32,239

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash7,6835,0335,7761,6563,5865,5712,3854,2375,4216,911
Accounts Receivable1,9852,2501,7081,6902,1002,9483,7744,3474,636
Inventory1,4131,2041,3841,6571,4981,5601,2211,2411,1661,195
PP&E5,0554,6644,5215,3338,8439,0664,4124,9805,0015,027
Assets31,00831,07632,97035,89738,59233,74931,74833,70733,55134,986
Accounts Payable1,7111,9832,6032,2022,5592,4871,5651,6642,2481,892
Long-Term Debt6,1305,3285,3767,2327,9817,2426,5506,4656,9756,895
Liabilities16,22315,43817,10322,25923,35618,76617,32417,36021,70420,859
Stockholders' Equity14,84315,71315,95613,62315,15414,85214,26616,17711,74114,031
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue18,80819,48421,24417,62112,30411,66014,04517,70222422,561
Cost of Revenue5,2775,5984,610538-2871,3943,221-14,4866,547
Gross Profit14,20715,64613,01111,76611,94712,65114,48114,71016,014
R&D3,6473,5663,8393,9043,7314,5345,9204,9406,4116,345
SG&A3,9463,6864,2034,2204,0844,0884,8414,9114,6874,551
Tax1,1821,5581,721-1613113525772,0414,1561,021
Net Income11,8624,5135,2602,5012,5802,0291,6314,5079754,947
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating4,0654,4914,8406,9413,5453,1481,8322,8505,2755,940
Cash Investing-4,380-3,812-1,437-6,727-5721,216-1,5721,480-66-874
Cash Financing-17-3,343-2,657-4,333-1,068-2,437-3,351-2,445-4,077-3,535